(Q37012289)

English

Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells

scientific article published on 28 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 August 2017

Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells (English)

1 reference

Europe PubMed Central

17 August 2017

enzyme replacement therapy

0 references

1 reference

based on heuristic

inferred from title

author name string

Suhrad G Banugaria

1

1 reference

Europe PubMed Central

17 August 2017

Trusha T Patel

2

1 reference

Europe PubMed Central

17 August 2017

Joanne Mackey

3

1 reference

Europe PubMed Central

17 August 2017

Stuti Das

4

1 reference

Europe PubMed Central

17 August 2017

Andrea Amalfitano

5

1 reference

Europe PubMed Central

17 August 2017

Amy S Rosenberg

6

1 reference

Europe PubMed Central

17 August 2017

Joel Charrow

7

1 reference

Europe PubMed Central

17 August 2017

Y-T Chen

8

1 reference

Europe PubMed Central

17 August 2017

Priya S Kishnani

9

1 reference

Europe PubMed Central

17 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

28 January 2012

1 reference

Europe PubMed Central

17 August 2017

Molecular Genetics and Metabolism

1 reference

Europe PubMed Central

17 August 2017

105

1 reference

Europe PubMed Central

17 August 2017

4

1 reference

Europe PubMed Central

17 August 2017

677-680

1 reference

Europe PubMed Central

17 August 2017

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

29 September 2017

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

29 September 2017

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

29 September 2017

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

29 September 2017

Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

29 September 2017

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

29 September 2017

The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

29 September 2017

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

29 September 2017

Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

29 September 2017

Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

29 September 2017

Assessment of gross motor skills of at-risk infants: predictive validity of the Alberta Infant Motor Scale.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

27 June 2018

Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

27 June 2018

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

27 June 2018

Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

27 June 2018

Expression of the insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

27 June 2018

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

4 September 2018

Elimination of antibodies to recombinant enzyme in Pompe's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

4 September 2018

Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

4 September 2018

A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3711263

4 September 2018

Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.019

7 January 2021

Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.019

7 January 2021

Identifiers

10.1016/J.YMGME.2012.01.019

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37012289&oldid=1666081364"